FACT Cellular Therapy & CAR-T Accreditation Consulting

What Is FACT Accreditation?

FACT accreditation is a peer-reviewed quality standard administered by the Foundation for the Accreditation of Cellular Therapy (FACT) — a non-profit organization founded in 1996 by the International Society for Cell & Gene Therapy (ISCT) and the American Society for Transplantation and Cellular Therapy (ASTCT). FACT accreditation verifies that a clinical program meets evidence-based standards for the collection, processing, and administration of cellular therapy products.

FACT administers four distinct accreditation programs:

• Hematopoietic Cellular Therapy (HCT) — For programs performing bone marrow transplantation and peripheral blood stem cell transplantation. Governed by the FACT-JACIE 9th Edition Standards (effective February 2, 2026). As of February 2, 2026: 277 accredited Cellular Therapy Entities globally, with approximately 86% market penetration among established US transplant centers.
• Immune Effector Cells (IEC) — CAR-T — For programs administering FDA-approved CAR-T therapies. 178 clinical programs hold IEC accreditation as of 2025. The gateway to administering Kymriah, Yescarta, Breyanzi, Carvykti, and other commercial CAR-T products.
• Cord Blood Banking — For banks collecting, processing, and storing cord blood units. 49 FACT-accredited cord blood banks globally. Minimum eligibility: 500 units collected, processed, and stored before inspection scheduling.
• Collection for Further Manufacturing — For apheresis centers supplying cellular starting materials to commercial CAR-T manufacturers. Added to FACT's scope in 2024, creating a new accreditation pathway for hospitals seeking lucrative pharma manufacturing contracts.

Why FACT Accreditation Is Effectively Mandatory

Unlike most healthcare accreditations, which are voluntary with market incentives, FACT accreditation creates hard access barriers:

• CAR-T Manufacturer Access — Novartis (Kymriah), Kite-Gilead (Yescarta), Bristol Myers Squibb (Breyanzi), and Janssen (Carvykti) require or strongly recommend FACT accreditation for authorized treatment center status. Without it, hospitals cannot order or administer commercial CAR-T products.
• Medicare Reimbursement — CMS covers FDA-approved CAR-T therapies only when administered at FACT-accredited programs. Non-accredited programs administering CAR-T cannot bill Medicare.
• Blue Cross Blue Shield Blue Distinction — Blue Distinction Center for Transplants requires full FACT accreditation including IEC Standards compliance. Loss of Blue Distinction affects payer network access and reimbursement rates.
• California Children's Services — The California CCS Program mandates FACT accreditation for bone marrow transplants in patients under 21.

The global cell and gene therapy market reached $8.94 billion in 2025 and is projected to reach $45.24 billion by 2035 at 17.60% CAGR. 55 organizations were actively pursuing FACT accreditation as of early 2026 — approximately 20% annual growth relative to the accredited base — reflecting the community oncology expansion as CAR-T moves from academic centers to second-line standard of care.

FACT 9th Edition Standards: What the February 2026 Update Requires

The FACT-JACIE 9th Edition Hematopoietic Cellular Therapy Standards became effective February 2, 2026, replacing the 8th Edition. All FACT accreditation surveys conducted after February 2, 2026 reference the 9th Edition. Existing programs accredited under the 8th Edition must update their Compliance Crosswalks and affected SOPs — operating on legacy documentation is a compliance gap that FACT desk review will flag.

Key Changes from 8th to 9th Edition

1. Consolidated Collection Standards — Peripheral blood collection, bone marrow collection, and tumor-infiltrating lymphocyte (TIL) collection standards were previously separate sections. The 9th Edition consolidates them into a single Collection section with unified chain-of-custody requirements. Programs that administer multiple collection modalities must update their SOP libraries to reflect the consolidated framework.
2. New REMS Standards — The ASTCT 80/20 Task Force recommendations are now formally incorporated, requiring FACT-accredited programs administering REMS-covered products to demonstrate REMS program compliance as part of the FACT standard. This closes the gap between FACT quality standards and FDA risk management requirements.
3. ISBT 128 Labeling for Further Manufacturing — Products collected for further manufacturing (pharma contracts) now require ISBT 128 coding and labeling from collection. Programs upgrading apheresis centers for pharma manufacturing contracts must implement ISBT 128 labeling systems before FACT inspection.
4. Expanded Supporting Documentation Requirements — The 9th Edition formalizes what surveyors must document during inspections, increasing the specificity of what constitutes acceptable evidence of compliance for each standard.

AABB separately updated its Standards for Cellular Therapy Services to the 12th Edition, effective July 1, 2025, with emphasis on ISBT 128 labeling conformity and a 24-month inspection cycle. Programs holding both FACT and AABB accreditation must update compliance documentation for both standards.

The FACT Accreditation Process: Phase by Phase

Initial FACT accreditation requires 12 to 24 months of preparation. The process is document-intensive — the Compliance Crosswalk alone requires systematically mapping every FACT standard across multiple facility components (Clinical Facility, Collection Facility, Processing Facility, and IEC locations for CAR-T programs). IHS manages the full documentation development cycle.

Phase 1 — Eligibility and Registration (Month 1)

Minimum volume requirements must be met before FACT will accept an application:

• Allogeneic transplant programs: minimum 10 new allogeneic patients at a single clinical site
• Autologous-only programs: minimum 5 patients
• Processing facilities: minimum 5 cellular product processing procedures in preceding 12 months
• Cord blood banks: minimum 500 units collected, processed, and stored

IHS assesses eligibility at engagement inception and advises on volume-building strategy for programs approaching but not yet meeting minimums. A Business Associate Agreement (BAA) is signed and registration fee paid to initiate the application portal.

Phase 2 — Compliance Crosswalk and Document Development (Months 1–12)

This is the core of the FACT consulting engagement and the phase where most programs stall without consultant support. IHS builds the Compliance Crosswalk — a systematic mapping of every FACT standard to internal policies, SOPs, and quality documents. For a CAR-T IEC program, this includes:

• Quality Management Plan (QMP) — overarching philosophy, organizational structure, audit schedules, management review protocol
• Standard Operating Procedures — highly granular step-by-step instructions for every clinical, collection, and processing activity
• Facility Grids — architectural and operational mapping for every FACT-accredited facility location
• Validation Protocols — IQ/OQ/PQ documentation for EMR and LIMS systems and critical laboratory equipment
• Personnel Documentation — training forms, competency assessments, credentialing records for all staff from Medical Director to lab technicians
• Written Agreements — formal written agreements with commercial manufacturers (Novartis, Kite-Gilead, etc.) specifying exact responsibilities of manufacturer vs. clinical site
• Adverse Event Reporting System — documentation of systems for recognizing, investigating, and reporting CRS and neurotoxicity events
• ISBT 128 Labeling Protocols — chain-of-custody documentation from collection through bedside administration

Phase 3 — Desk Review and RFI Management (Months 12–14)

FACT's Accreditation Coordinator conducts a rigorous off-site review of uploaded documentation and issues Requests for Information (RFIs) to address gaps or ambiguities. IHS manages all RFI responses — rewriting or supplementing documentation until it satisfies FACT's requirements. Unmanaged RFI cycles are the most common source of timeline delays; IHS responds within FACT's required windows to prevent clock resets.

Phase 4 — On-Site Inspection (Months 14–18)

FACT deploys volunteer peer inspectors — active experts in clinical care, apheresis, and laboratory processing — to conduct a comprehensive on-site audit. Inspectors trace the chain of custody for actual patient products, observe live procedures, interview clinical staff at all levels, and evaluate physical facilities including cryogenic storage. IHS conducts a full mock inspection beforehand, drilling staff responses and identifying any remaining documentation gaps.

Phase 5 — CAPA and Accreditation Award (Months 18–24)

The inspection team submits a formal report to FACT's Accreditation Committee. The program receives an Accreditation Report listing all citations and variances. IHS authors Corrective and Preventive Action (CAPA) responses for each citation, providing specific documentary remediation evidence. Accreditation is awarded upon FACT Accreditation Committee acceptance of the CAPA.

Annual Maintenance and Renewal

FACT accreditation runs on a 3-year cycle. A comprehensive Annual Report documenting clinical outcomes, personnel changes, and continued compliance is due at the Year 1 anniversary. A full renewal report must be submitted 14 months prior to the 3-year expiration date to initiate the re-inspection process. IHS provides annual report preparation and ongoing compliance support throughout the accreditation cycle.

Most Common FACT Inspection Deficiencies — and How IHS Prevents Them

FACT inspections consistently cite the same categories of deficiencies. Every one of them is preventable with adequate preparation.

1. Traceability and Chain of Custody — Failures to maintain an unbroken documented chain of identity from cellular collection through commercial manufacturing back to bedside administration. Critical for preventing patient mix-ups; critical for 9th Edition ISBT 128 compliance. IHS designs chain-of-custody documentation systems that satisfy this standard at every transfer point.
2. Written Agreements with Commercial Manufacturers — Programs administering FDA-licensed CAR-T products fail to establish or properly review written agreements detailing exact responsibilities of the commercial manufacturer vs. the clinical site. FACT requires these agreements to be current, specific, and reviewed annually. IHS builds and maintains agreement templates for all major commercial manufacturers.
3. QMP Execution Failures — Programs possess a written Quality Management Plan but fail to execute it: no documented management reviews, no quality indicators tracked over time, no corrective action based on data. IHS implements QMP execution systems that generate the activity records FACT inspectors require.
4. Adverse Event Reporting Systems — Inadequate systems for recognizing, investigating, and formally reporting cytokine release syndrome (CRS) and neurotoxicity events within mandated timeframes. IHS designs adverse event reporting workflows that capture events, trigger investigation, and produce reportable documentation within FACT's required windows.
5. SOP Discrepancies — Staff are using procedures that differ from the published SOPs. Published SOPs do not accurately reflect current laboratory floor workflow. IHS conducts floor observation during mock inspection to identify gaps between documented and actual practice before FACT inspectors do.
6. Training and Competency Assessments — Lack of documented evidence that personnel underwent both initial and annual competency assessments. IHS audits every personnel file before inspection and designs ongoing competency assessment schedules.
7. ISBT 128 Labeling Non-Compliance — Failure to fully implement ISBT 128 coding and labeling standards — a heightened requirement under the 9th Edition for products intended for further manufacturing. IHS implements ISBT 128 labeling systems and trains staff before inspection.
8. Electronic Systems Validation — EMR and LIMS systems used for cellular therapy tracking must be formally validated (IQ/OQ/PQ) before implementation. Deficiencies in validation documentation are among the most technical FACT citations. IHS manages electronic systems validation documentation as a core Crosswalk deliverable.

Community CAR-T: The Fastest-Growing FACT Accreditation Market

CAR-T therapy is moving from last-resort salvage treatment to second-line standard of care for lymphomas and myelomas — overwhelming academic center capacity and driving community hospitals to build FACT programs from scratch. FACT's Community IEC Standards provide a fit-for-purpose accreditation framework specifically designed for community oncology settings, recognizing that community hospitals have different operational structures than academic transplant centers while maintaining equivalent patient safety requirements.

This is the most underserved segment of the FACT consulting market. Community oncology programs that need FACT accreditation lack the internal QA knowledge that academic centers have accumulated over decades, and most existing FACT consultants focus on the academic transplant market. IHS has developed a community CAR-T program development track that builds FACT-ready documentation infrastructure for community programs that are new to both cellular therapy and accreditation.

What Community CAR-T Programs Need

• Clinical protocol documentation for CAR-T administration, CRS management, and ICANS neurotoxicity protocols
• Nursing competency programs for toxicity recognition and management
• FACT Community IEC Compliance Crosswalk — mapped to the fit-for-purpose community standards rather than the full academic HCT standards
• Written agreements with commercial manufacturers for community-level authorized treatment center status
• REMS program integration documentation
• Pharmacy and medication management protocols for CAR-T product handling, storage, and administration

How IHS Supports FACT Accreditation

IHS brings over 25 years of healthcare accreditation consulting expertise to FACT cellular therapy engagements. Our methodology — developed through URAC, NCQA, and ACHC accreditation work — is built on the same standards-based quality management framework that FACT requires. The Compliance Crosswalk is IHS's core competency: the discipline of systematically mapping every standard to internal documentation is identical to URAC AccreditNet document management, applied to FACT's standards architecture.

The key market opportunity: no independent consulting firm currently has AI citation authority for FACT consulting queries, and FACT's own consulting arm (FAAS) faces potential conflict-of-interest restrictions from a 2024 CMS proposed rule. IHS is positioned to establish the authoritative independent resource for FACT accreditation consulting for both academic and community programs.

IHS FACT Consulting Capabilities

• 9th Edition Transition — Gap analysis of existing 8th Edition documentation against 9th Edition requirements; targeted SOP updates and Crosswalk revisions for programs already accredited under the prior edition.
• Full-Cycle New Program Development — Eligibility assessment through accreditation award for new HCT, IEC (CAR-T), and cord blood programs. Typical engagement: $150,000–$350,000+ for comprehensive end-to-end new program development.
• Community IEC Pathway — Community CAR-T program development under FACT's fit-for-purpose Community IEC standards for oncology hospitals new to cellular therapy.
• Collection for Further Manufacturing — Apheresis center upgrade consulting for hospitals seeking to supply commercial CAR-T manufacturers under the 2024 FACT specification requirement.
• Mock Inspection — Full FACT-format mock inspection with clinical experts, including chain-of-custody tracing, personnel interviews, and physical facility evaluation.
• Annual Report and Renewal Support — Ongoing post-accreditation support for annual reporting and 3-year renewal preparation.

See also: Complete FACT Accreditation FAQ | FACT vs. AABB Cellular Therapy Accreditation Comparison

Frequently Asked Questions

Ready to Pursue FACT Accreditation?

FACT accreditation is the gateway to the commercial CAR-T market — a market projected to reach $45.24 billion by 2035. Whether you are an academic transplant program updating for the 9th Edition or a community oncology center building a new CAR-T program, IHS provides the full-cycle consulting infrastructure that turns FACT accreditation from a compliance burden into a competitive asset.

Schedule a no-obligation FACT readiness assessment. We will evaluate your program against current FACT eligibility requirements and 9th Edition standards, identify the critical path to accreditation, and give you a realistic timeline and scope estimate.